Out of the Lab: Operationalizing Cell and Gene Therapy

Nicholas (Nico) Crudele
  • 0.0 (0)
  • ENTREPRENEURSHIP

tech transfer, process control, travel requirements, audits These silent operational breakdowns prevent life-saving cell and gene therapy treatments from ever reaching patients, and kill IP-backed companies. This show is for executives on the path to clinic, de-risking their clinical assets. Leverage insights hard-earned from countless years in the industry, ranging from the manufacturing floor through to leadership. Transform operations from your biggest risk into your greatest asset. See, understand and prepare for the challenges ahead on your clinical journey.

  1. 6D AGO

    "Visceral Doesn't Count": The Cultural Divide Between Research & GMP | Tatyana Matveeva

    In this episode of the Out of the Lab Podcast, we sit down with Tatyana Matveeva, head of cGMP operations at Harvard, to discuss the documentation challenges in cell and gene therapy tech transfer. We dive deep into the cultural divide between GMP operations and research environments. Tatyana explains why therapies developed over decades in an academic setting struggle to transition into clinical manufacturing. We cover the massive financial and time costs associated with deviations, why process validation in a new facility is mandatory, and why "visceral" lab knowledge must be translated into concrete, GMP-grade documentation to protect patients and ensure regulatory approval. Key Topics Discussed: The fundamental differences in documentation requirements between research and GMP. Why successful research runs do not guarantee a seamless tech transfer. The exponential time and financial costs of CAPA investigations and scrapped batches. Why "visceral" understanding of a process isn't enough to train operators or run subsequent batches. Show Notes: 00:00:37 - The Cultural Divide Between Research and GMP Discussing how therapies originating from decades of lab work must transition into a GMP environment. Scientists often face challenges adapting to the full scope of GMP compliance and documentation. 00:07:45 - The Purpose of Documentation: Research vs. GMP Research documentation focuses primarily on reproducibility. GMP documentation requires strict traceability—including exact dates, times, and personnel flow—to ensure patient safety and product integrity. 00:14:15 - The Exponential Cost of Deviations Unlike in research, mistakes in clinical manufacturing can cause operations to stop completely and require materials to be scrapped. A single week of delay can easily snowball into three to five weeks of lost time for the patient. 00:17:06 - "Visceral Doesn't Count" in Manufacturing While scientists may have a "visceral" understanding of their processes, GMP requires explicit, concrete articulation for training and batch replication. 00:18:00 - The Illusion of Seamless Tech Transfers Replicating a process successfully in a research setting does not guarantee a successful tech transfer if the team lacks GMP-grade batch production records. 00:20:47 - CAPA Investigations: The Month-Long Delay Identifying root causes and implementing Corrective and Preventive Actions (CAPA) after a deviation can halt operations for a month or more. 00:24:43 - Dry Runs, Sandbox Runs, and Facility Validation Moving to a new facility introduces new variables, making pre-validation dry runs and expensive engineering runs crucial for uncovering operational vulnerabilities. 00:28:33 - The Ultimate Goal: Patient Safety and Regulatory Approval Rigorous documentation and safe processes are ultimately required to secure regulatory approval and prevent adverse events in patients.

    30 min

  2. APR 5

    Surviving Stage 4 Cancer: Melinda Bachini on Cell Therapy Patient Access & Barriers

    In this episode of Out of the Lab, we sit down with patient advocate Melinda Bachini to explore the real-world operational barriers holding back access to cell and gene therapies. Melinda shares her incredible journey from receiving a stage four terminal cholangiocarcinoma diagnosis 16 years ago to becoming a pioneer in cell therapy treatments at the National Cancer Institute (NCI). Her story, which has been featured in the Science journal and the New York Times, highlights the massive gap between scientific breakthroughs and actual patient access. We dive deep into the heavy logistical and financial burdens placed on patients, including her own experience traveling from Billings, Montana, to Bethesda, Maryland, while arranging care for her six children. Key topics covered in this episode: The immense travel and financial obstacles rural patients face when trying to access clinical trials. Why decentralized manufacturing could be the "next frontier" for bringing individualized cell therapies to community settings. The critical need to include a patient advocate's voice in clinical trial design and research from the very beginning. Why requiring patients to progress on a standard of care before entering an experimental trial is a major hurdle that needs to change. The forward-thinking concept of banking a patient's cells preventatively after surgery to prepare for potential cancer recurrence. Melinda’s perspective is a crucial reminder for companies and researchers that medical breakthroughs only change lives if patients can actually reach them. Show Notes: 00:15 - 03:02: Operational Barriers to Access 03:02 - 04:32: The Challenge of Manufacturing and Rural Access 04:32 - 06:14: Impact on Caregivers and Families 06:14 - 07:50: Future Frontiers in Treatment 07:50 - 11:47: Improving the Clinical Trial Process 11:47 - 13:46: Personal Experience with TIL Therapy 13:46 - 15:02: Evolution of Accessibility 15:02 - 18:43: Personal Story and Birth of Advocacy

    19 min

  3. MAR 21

    The Cost of Waiting: Why Speed to Patient is the Ultimate Metric

    In this episode, we sit down with Jesus Zurdo, a patient advocate and bioprocessing veteran who has seen the cell therapy journey from both the cleanroom and the hospital bed. We challenge the industry’s obsession with Cost of Goods Sold (COGS) and explore why logistics and manufacturing speed are the true barriers to saving lives. Key topics discussed: The "Wait Time" Crisis: Why 26% of patients die while waiting for a manufacturing slot. Quality over Cost: How low-quality viral vectors lead to higher doses and increased toxicity . The "One and Done" Trap: Why the "cure" narrative may be digging an operational hole for the industry . The Future of In Vivo: How in vivo CAR T could eliminate lymphodepletion and wait times entirely . Show notes: 00:07 Why COGS is the wrong metric for accessibility. 02:22 The "sCARy" reality of transgene quality and liver toxicity . 05:50 The Wait Time Crisis: Breaking down the 26% mortality statistic. 16:50 The "One and Done" trap and the necessity of managing cancer as a chronic condition. 23:35 The Dream of In Vivo: Removing the logistical and biological hurdles of Ex Vivo. 32:20 Point-of-care manufacturing and "Fast CARs" as the operational bridge.

    46 min

  4. MAR 21

    Decentralization, Physician Adoption, and Data Sharing

    In this episode of the Out of the Lab: Operationalizing Cell Therapy Podcast, host Nico is joined by Claudia Zylberberg to discuss why, despite two decades of innovation and improved manufacturing capability, patient access to cell therapies like CAR T is still limited by adoption and operational issues rather than science. She argues that decentralization should mean smarter, data-trusted orchestration across locations and bringing manufacturing closer to patients through hospital-centered models. Key barriers include physician and hospital discomfort due to training gaps around indications and post-infusion management (e.g., cytokine storm), and fragmented data across EHRs, manufacturers/CDMOs, and post-infusion hospital records. Claudia emphasizes the need for consortia or registries to share blinded data, stronger digital infrastructure, and better integration among hospitals, manufacturers, and payers, with scaling and operational alignment helping reduce costs over time. Chapters: 00:20 Industry Status and Decentralization 02:11 Physician Adoption Barriers 04:22 Training for CAR T Care 06:13 Hospitals Offices and Digital Orchestration 09:27 Small Hospitals and Data Silos 13:24 Blinded Data and AI Potential 15:33 Who Owns the Data 17:55 Decentralization Beyond Manufacturing 19:04 Reimbursement and Payer Dynamics 21:31 Integration and Data Sharing Vision 22:45 Future Outlook and Closing

    24 min

  5. MAR 17

    The "Gently" Trap: Navigating the Realities of Cell & Gene Therapy Assay Transfer

    Guest: Jennifer Hayne, VP & Head of Biologics Analytics Services at Catalent In this technical deep dive of the Out of the Lab podcast, we explore the often-overlooked nuances of transferring assays from early-stage research into a GMP (Good Manufacturing Practice) environment.  Jennifer from Catalent joins us to discuss why "common sense" in a research lab doesn't always translate to a scalable manufacturing process. We break down the trends in missing documentation, the impact of human variability on results, and how to future-proof your protocols. Key Topics Covered: The Language of Science:  Why qualitative terms like "gently resuspend" create variability and how to replace them with specific, measurable steps. Modality Trends:  Comparing the "de novo" nature of cell therapy with the emerging platform approaches in gene therapy. The Antibody Renaissance:  How bispecifics and ADCs (Antibody Drug Conjugates) are requiring more complex technical discussions than traditional antibodies once did. Scientist-to-Scientist Collaboration:  When documentation isn't enough, how Catalent uses site visits to identify hidden sources of variability. Best Practices for Future Transfers:  -   Why you need at least two sources for critical raw materials.  -   Testing the "limits" of your assay (e.g., what happens at 10 minutes instead of 5?).  -   Designing for the 8-hour workday vs. the 48-hour postdoc marathon. Show Notes 00:02 - Introduction Nicholas Crudele welcomes Jennifer, VP at Catalent, to discuss trends in incoming procedures and assay transfers. 00:39 - Identifying Incomplete Documentation Early-stage clients often have incomplete documentation from a GMP perspective, even if it is sufficient to run an initial assay. A significant trend in missing information is the lack of specificity for individual steps, often due to assumptions made by early-stage researchers. 02:18 - Human Variability and Standardized Techniques Human variability is a major factor in lab results, as different individuals may perform tasks like pipetting or vegetable cutting differently. GMP scientists can help identify where increased specificity is needed to control this variability. Vague qualitative terms, such as "gently resuspend," are a common source of misunderstanding. 04:46 - Best Practices for Resolving Variability Labs use stringent techniques to reduce variability, such as changing vague language to specific instructions (e.g., "invert the tube three times"). If standardized techniques are insufficient, scientist-to-scientist collaboration, including site visits to observe techniques firsthand, is the next step. 07:27 - Modality-Specific Challenges Cell Therapy: Every assay is often unique (denovo) and requires technical discussion and experimentation. These materials are sensitive with short shelf lives. Gene Therapy: This modality is increasingly using more stable, platform-type approaches with less variability. Antibodies: While established, new innovations like bispecifics and ADCs are requiring closer technical discussions than in the past. 09:37 - The Benefits of Platform Technologies Platform approaches allow for faster and more cost-effective processes by repeating established exercises with minor changes. Working with the same lab over time allows for better tracking and quicker resolution of recurring method challenges. 11:47 - Advice for Future Tech Transfers Raw Materials: Ensure critical raw materials are not single-sourced; ideally, have at least two tested sources to avoid supply chain disruptions. Test Assay Limits: Experiment with the timing and limitations of steps (e.g., what happens if a five-minute step is done for ten minutes?) and document the findings for the service provider. Staffing Realities: Consider the practicality of running assays long-term; designs requiring 48 hours of continuous attention are expensive to staff in a traditional GMP lab.

    13 min

  6. MAR 11

    Laying the Rails for Advanced Therapies: Paul Chun on Cell & Gene Operations

    In this episode, we sit down with guest Paul Chun to explore the complex operational challenges within the cell and gene therapy sector. Chun grounds the conversation in the powerful story of Melinda Bachini, the first GI tumor patient to receive tumor-infiltrating lymphocyte (TIL) therapy for cholangiocarcinoma. Despite her success over a decade ago, Chun explains why this life-saving process remains largely inaccessible. We dive deep into the business and operational hurdles of biotech, discussing why companies often pass on niche diagnoses, the intense resource realities of clinical trial design, and why high attrition rates mean fewer than one in ten eligible patients actually make it to treatment. Chun also breaks down the geographic and manufacturing bottlenecks that persist today, noting that while industry leaders have massively expanded their manufacturing capacity, upstream bottlenecks and "last mile" access issues keep actual market adoption plateaued. Discover how new models building standalone clinics aim to expand the catchment area for patients, and learn about the biotech social contract that justifies the cost of high innovation. Chapters / Timestamps: 0:00 - 00:33: Introduction and a look at operational challenges in cell and gene therapy. 00:33 - 03:33: The story of Melinda Bachini and the specific challenges of cholangiocarcinoma. 03:33 - 06:14: Operational and clinical advocacy, featuring Dr. Simon Turcotte's role in Bachini's treatment. 06:14 - 09:55: Biotech investment, market dynamics, and how patient advocacy shifts the calculus for niche diagnoses. 09:55 - 14:30: Clinical trial design realities, high patient attrition rates, and new TCR-based developments. 14:30 - 17:15: Geographic barriers, the high burden of finding trials, and patient access. 17:15 - 21:18: Manufacturing capacity expansion vs. upstream bottlenecks and market adoption. 21:18 - 28:54: Solving the "last mile" with new clinical models like NexCure. 28:54 - 34:10: Supply chain risks in the last yards of the last miles and cultural shifts among specialists like rheumatologists. 34:10 - 41:25: The "railroad" infrastructure analogy and the complications of cross-border trial participation. 41:25 - 51:44: Financial friction at clinical centers and RA Capital’s "biotech social contract". 51:44 - 01:01:20: The high-risk nature of biotech and the critical power of patient stories.

    1h 1m

  7. FEB 24

    You Don't Know What You Don't Know: The Hidden Traps in Tech Transfer with François-Xavier Lacasse

    Why does a process that works perfectly in a university lab suddenly fail when it hits a manufacturing facility? In this episode, we sit down with François-Xavier (FX) Lacasse, a 28-year industry veteran, to unpack the notorious friction of tech transfer. We dive into the fundamental language barrier between academia ("research for research") and industry ("research for development"), and why strict GMP/GLP compliance is such a difficult bridge to cross. FX shares some brilliant analogies to explain the reality of scaling up like why changing the pan you’ve cooked a recipe in for 15 years suddenly ruins the dish, or how failing to document a seemingly obvious detail (like the exact temperature of the water) leads to massive reproducibility failures in biotech with a much higher cost than a burnt omelet. Ultimately, it comes down to a simple truth: you don't know what you don't know. In this episode, we cover: - Understanding the physical realities of scaling from an Eppendorf tube to a bioreactor. - The danger of tacit knowledge and unwritten steps in Standard Operating Procedures. - Why documentation is the ultimate crux of successful tech transfer. - How early-stage oversights compound into massive costs during clinical trials.Show Notes: [00:00:22] – Introduction: FX’s background and 28 years of experience in pharmaceutical development. [00:01:26] – The Language Barrier: Understanding the massive gap between "Research for Research" (academia) and "Research for Development" (industry). [00:02:27] – Why you must involve Contract Development and Manufacturing Organizations (CDMOs) as early as possible to anticipate operational pitfalls. [00:04:21] – The Water Temperature Dilemma: How unwritten, tacit knowledge ruins reproducibility when handing off a procedure to another operator. [00:07:35] – Why comprehensive documentation is the absolute "crux of the matter" in tech transfer. [00:12:42] – The massive financial impact of failing to document operational details before hitting multi-million dollar clinical trials. [00:18:59] – The "Cooking Pan" Analogy: Why scaling up from an Eppendorf tube to a bioreactor breaks your process due to heat and mass transfer changes. [00:20:10] – "You don't know what you don't know" – Uncovering the hidden traps in early-stage process development. Connect with us on LinkedIn: Nicholas Crudele (host): François-Xavier (FX) Lacasse (guest):learn how Method Made addresses documentation challenges for tech transfer:

    21 min

  8. FEB 21

    Decentralizing the Cure: The Road to Community-Based CAR-T

    In this episode, host Nico sits down with repeat guest Lee Buckler to tackle the "80/20" problem in cell and gene therapy: the fact that while 80% of patients are treated in community settings, CAR-T therapies are currently stuck in high-level academic centers. We explore the history of patient access from the stem cell transplant model to the lessons learned from Dendreon’s Provenge and map out the infrastructure needed to bring these cures to the local level. From the "10-mile rule" of patient attrition to the massive financial hurdles of carrying multi-million dollar therapies on a hospital’s books, this conversation digs into the operational reality of scaling life-saving science Key Discussion Points The 10-Mile Rule: Why every 10 miles of distance from a treatment center results in a 6.2% drop in the likelihood of a patient receiving CAR-T. Infrastructure vs. Business Hurdles: Analyzing why the $500,000 to $3 million upfront cost of therapy creates massive cash-flow barriers for community hospitals.Decentralizing the "Vein-to-Vein" Process: How Blood Centers of America (BCA) and FACT are establishing new standards for local apheresis and infusion. Safety and Remote Monitoring: How wearable tech and reduced FDA REMS requirements are allowing patients to recover at home sooner. The Future of Cost: A look at how non-profit models and 5-year ROI data are shifting the payer landscape.Show Notes 00:21 – The dual history of cell therapy: Stem cell transplants vs. Provenge. 05:43 – The community access gap: Why CAR-T sales have plateaued at 20%. 11:48 – Expanding into autoimmune: Why local delivery is no longer optional. 19:30 – Logistics and Cryopreservation: Building a national infrastructure. 34:33 – Financial bottlenecks and the reality of reimbursement. 51:41 – Advancements in remote monitoring and patient safety. 58:48 – Insurance, ROI, and the rise of generic models.

    1h 4m
See All (26)

About

tech transfer, process control, travel requirements, audits These silent operational breakdowns prevent life-saving cell and gene therapy treatments from ever reaching patients, and kill IP-backed companies. This show is for executives on the path to clinic, de-risking their clinical assets. Leverage insights hard-earned from countless years in the industry, ranging from the manufacturing floor through to leadership. Transform operations from your biggest risk into your greatest asset. See, understand and prepare for the challenges ahead on your clinical journey.

Information